Over the last 12 months, one SELLAS Life Sciences Group, Inc. the people running the company purchased shares at market prices, about $101,000 in total, and none of them sold.
Biggest single buyer: Kalin Katherine Bach, Director, with roughly $101,000.
Big money check: 192 institutions held SLS as of Q2 2026, and more funds bought than sold. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Kalin Katherine Bach | Director | Buy | 63,400 | $1.59 | $101K | SEC |
| Jun 13, 2025 | VAN NOSTRAND ROBERT L | Director | Buy | 10,000 | $1.48 | $15K | SEC |
| Jun 2, 2025 | Wasman Jane | Director | Buy | 20,000 | $1.69 | $34K | SEC |
| May 22, 2025 | Kalin Katherine Bach | Director | Buy | 20,000 | $1.80 | $36K | SEC |
In the last 12 months SELLAS Life Sciences Group, Inc. insiders made open-market purchases worth about $101,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in SLS was filed on 2025-11-21.
192 investment managers reported holding SLS in SEC Form 13F filings for Q2 2026.
No congressional trades in SLS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).